NCT01465035已完成1 期
A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Safety of co-administration of MVA-NP+M1 and seasonal influenza vaccine.
研究概览
简要总结
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with seasonal influenza vaccine. All volunteers recruited will be adults aged 50 and over.
The rationale behind co-administration of MVA-NP+M1 with a seasonal influenza vaccine (TIV) is that the immune system will be stimulated to produce both influenza specific T cells and influenza specific antibodies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men and women aged 50 or over with no upper age limit
- •Resident in or near Oxford for the duration of the vaccination study
- •Able and willing (in the Investigators' opinions) to comply with all study requirements
- •Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
- •For females who are not post-menopausal, a negative pregnancy test on the day of vaccination and agreement to practice effective contraception for the duration of the study
- •Agreement to refrain from blood donation during the course of the study
- •Written informed consent
排除标准
- •Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
- •Receipt of MVA or smallpox vaccines in the last 5 years, or receipt of the 2011/12 seasonal influenza vaccine prior to entering the study.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- •Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products
- •Any history of anaphylaxis in reaction to vaccination
- •Recent treatment for cancer (except basal cell carcinoma and cervical carcinoma in situ)
- •History of serious psychiatric condition
- •Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)
- •Seropositive for hepatitis B surface (HBsAg) or hepatitis C virus (antibodies to HCV)
- •For pre-menopausal females, pregnancy, lactation or willingness/intention to become pregnant during the study
- •Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study.
- •No response / confirmation from GP regarding previous medical history
结局指标
主要结局
Safety of co-administration of MVA-NP+M1 and seasonal influenza vaccine.
时间窗: Participants will be followed for the duration of the study, an expected average of 6 months
The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.
次要结局
- Immune response generated by co-administration of MVA-NP+M1 and seasonal influenza vaccine(Participants will be followed for the duration of the study, an expected average of 6 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza VaccineInfluenzaNCT02014168University of Oxford3
招募中
1 期
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined VaccinePertussisTetanusDiphtheriaNCT06184542Institute of Medical Biology, Chinese Academy of Medical Sciences460
已完成
1 期
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant VaccineHPV InfectionsNCT03900572Shanghai Zerun Biotechnology Co.,Ltd90
已完成
1 期
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy AdultsRift Valley FeverRVFNCT04672824University of Oxford30
撤回
2 期
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and AboveCOVID-19NCT05663086Guangzhou Patronus Biotech Co., Ltd.